CoChat

Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma

Open access
Watt, S A, Pourreyron, C, Purdie, K, Hogan, C, Cole, C L, Foster, N, Pratt, N, Bourdon, J-C, Appleyard, V, Murray, K, Thompson, A M, Mao, X, Mein, C, Bruckner-Tuderman, L, Evans, A, McGrath, J A, Proby, C M, Foerster, J, Leigh, I M, South, A P · 2011 · Oncogene
Cited by 76

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Identifying therapeutic targets for cancer treatment relies on consistent changes within particular types or sub-types of malignancy. The ability to define either consistent changes or sub-types of malignancy is often masked by tumor heterogeneity. To elucidate therapeutic targets in cutaneous squamous cell carcinoma (cSCC), the most frequent skin neoplasm with malignant potential, we have developed an integrated approach to gene expression profiling beginning with primary keratinocytes in culture. Candidate drivers of cSCC development were derived by first defining a set of in vitro cancer genes and then comparing their expression in a range of clinical data sets containing normal skin, cSCC and the benign hyper-proliferative condition psoriasis. A small interfering RNA (siRNA) screen of the resulting 21 upregulated genes has yielded targets capable of reducing xenograft tumor volume in vivo. Small-molecule inhibitors for one target, Polo-like kinase-1 (PLK1), are already in clinical trials for other malignancies, and our data show efficacy in cSCC. Another target, C20orf20, is identified as being overexpressed in cSCC, and siRNA-mediated knockdown induces apoptosis in vitro and reduces tumor growth in vivo. Thus, our approach has shown established and uncharacterized drivers of tumorigenesis with potent efficacy as therapeutic targets for the treatment of cSCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2011.180

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 76

Metadata

Authors
Watt, S. A., Pourreyron, C., Purdie, K., Hogan, C., Cole, C. L., Foster, N., Pratt, N., Bourdon, J.-C., Appleyard, V, Murray, K., Thompson, A. M., Mao, X., Mein, C., Bruckner-Tuderman, L., Evans, A., McGrath, J. A., Proby, C. M., Foerster, J., Leigh, I. M., & South, A. P.
Venue
Oncogene
Published
2011-05-23
Volume
30
Issue
46
Pages
4666-4677
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2012357495
Cited by
76
References
7
FWCI
4.32
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. https://app.cochat.ai/papers/10.1038/onc.2011.180
The paper
Watt, S. A., Pourreyron, C., Purdie, K., Hogan, C., Cole, C. L., Foster, N., Pratt, N., Bourdon, J.-C., Appleyard, V, Murray, K., Thompson, A. M., Mao, X., Mein, C., Bruckner-Tuderman, L., Evans, A., McGrath, J. A., Proby, C. M., Foerster, J., Leigh, I. M., & South, A. P. (2011). Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene. https://doi.org/10.1038/onc.2011.180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.